Systemic Therapy Options for Patients With Unresectable Melanoma
| العنوان: | Systemic Therapy Options for Patients With Unresectable Melanoma |
|---|---|
| المؤلفون: | Paul B. Chapman, Caroline Robert, Ragini R. Kudchadkar, Melinda L. Yushak |
| المصدر: | American Society of Clinical Oncology Educational Book. :661-672 |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Proto-Oncogene Proteins B-raf, 0301 basic medicine, Oncology, medicine.medical_specialty, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions, MAP Kinase Kinase Kinase 1, Disease, Systemic therapy, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, In patient, Molecular Targeted Therapy, Adverse effect, Melanoma, Protein Kinase Inhibitors, business.industry, General Medicine, medicine.disease, Clinical trial, Treatment Outcome, 030104 developmental biology, 030220 oncology & carcinogenesis, Mutation, Immunotherapy, business, Progressive disease, V600E |
| الوصف: | There has been a therapeutic revolution in the treatment of metastatic melanoma over the past decade. Patients presenting with inoperable disease have several therapeutic options, which can include both targeted and immune therapy. Immune checkpoint inhibitors have demonstrated an improvement in overall survival and led to some durable responses. However, toxicity, especially in combination regimens, can be severe. Adverse events should be anticipated, diagnosed as early as possible, monitored, and managed. Combination BRAF and MEK inhibition has also been shown to improve overall survival in patients with V600E-mutated melanoma. Responses to therapy are often rapid, and treatment is not associated with immune-related adverse events. Current trials are under way to determine which option is optimal as frontline therapy for patients with V600E melanoma. In patients with progressive disease despite standard therapies, clinical trials are recommended. There are several promising agents in development. |
| تدمد: | 1548-8756 1548-8748 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0173e4f3b185b3bad9ce4e3f188cd05Test https://doi.org/10.1200/edbk_174934Test |
| رقم الانضمام: | edsair.doi.dedup.....b0173e4f3b185b3bad9ce4e3f188cd05 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15488756 15488748 |
|---|